

19th July, 2019

- | | |
|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
| <p>Scrip Code: 500087</p> | <p>Scrip Code: CIPLA EQ</p> |

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Subject: USFDA cGMP inspection completed at Cipla's API manufacturing facility in Virgonagar, Bengaluru

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection at our API manufacturing facility in Virgonagar, Bengaluru from 15th June, 2019 to 19th June, 2019.

The inspection ended with 7 observations, none of which were repeat or related to data integrity. The Company will respond to the agency within the stipulated timeline.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Cipla Limited



Karan Tanna
Associate Director
Corporate Secretarial